MRZM (Marizyme) E10: $-2.59 (As of Sep. 2024)


MRZM Marizyme Inc MRZM
12 GF Score
Price $0.00
View Full Analysis

What is Marizyme E10?

Marizyme MRZM -99.67% 12 E10 is $-2.59 as of Sep. 2024. GuruFocus rates MRZM with a GF Score™ of 12/100.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Marizyme's adjusted earnings per share data for the three months ended in Sep. 2024 was $-0.010. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-2.59 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-27), Marizyme's current stock price is $0.0003. Marizyme's E10 for the quarter that ended in Sep. 2024 was $-2.59. Marizyme's Shiller PE Ratio of today is .


Marizyme  (OTCPK:MRZM) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Marizyme E10 Related Terms


Marizyme E10 Historical Data

* Premium members only.

The historical data trend for Marizyme's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marizyme E10 Chart

Marizyme Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.88 -4.94 -5.32 -5.55 -5.18

Marizyme Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.62 -5.18 -3.07 -2.76 -2.59

MRZM vs CNBX, XSNX, NBIO: E10 Comparison

For the Biotechnology subindustry, Marizyme's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Marizyme Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Marizyme's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Marizyme's Shiller PE Ratio falls into.


MRZM
12GF Score
Marizyme Inc MRZM
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Marizyme E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Marizyme's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.01/315.3010*315.3010
=-0.010

Current CPI (Sep. 2024) = 315.3010.

Marizyme Quarterly Data

per share eps CPI Adj_EPS
201203 -11.861 229.392 -16.303
201206 -0.870 229.478 -1.195
201209 -0.397 231.407 -0.541
201212 0.806 229.601 1.107
201303 -1.296 232.773 -1.755
201306 -0.188 233.504 -0.254
201309 -1.082 234.149 -1.457
201312 0.229 233.049 0.310
201412 0.000 234.812 0.000
201512 0.000 236.525 0.000
201612 0.000 241.432 0.000
201709 0.036 246.819 0.046
201712 -0.578 246.524 -0.739
201803 -0.040 249.554 -0.051
201806 -0.060 251.989 -0.075
201809 -0.070 252.439 -0.087
201812 -0.003 251.233 -0.004
201903 -0.003 254.202 -0.004
201906 -0.010 256.143 -0.012
201909 -0.030 256.759 -0.037
201912 -0.010 256.974 -0.012
202003 -0.020 258.115 -0.024
202006 -0.020 257.797 -0.024
202009 -0.070 260.280 -0.085
202012 -0.090 260.474 -0.109
202103 -0.080 264.877 -0.095
202106 -0.050 271.696 -0.058
202109 -0.050 274.310 -0.057
202112 -0.160 278.802 -0.181
202203 -0.150 287.504 -0.165
202206 -0.170 296.311 -0.181
202209 -0.040 296.808 -0.042
202212 -0.580 296.797 -0.616
202303 -0.060 301.836 -0.063
202306 -0.480 305.109 -0.496
202309 -0.580 307.789 -0.594
202312 -0.020 306.746 -0.021
202403 -0.050 312.332 -0.050
202406 -0.030 314.175 -0.030
202409 -0.010 315.301 -0.010

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-2.59 mean?
Marizyme (MRZM) has a E10 of $-2.59 as of Sep. 2024. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Marizyme and its competitors.
Is Marizyme's E10 too high?
Marizyme's current E10 is $-2.59. Overall, Marizyme has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Marizyme's E10 compare to CNBX and XSNX?
Marizyme's E10 of $-2.59 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Marizyme and its competitors. Marizyme's current E10 is $-2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Marizyme stock overvalued right now?
Marizyme (MRZM) has a current E10 of $-2.59. The current E10 is $-2.59. Marizyme's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Marizyme (MRZM), the current E10 is $-2.59 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Marizyme Business Description

Address 555 Heritage Drive, Suite 205, Jupiter, FL, USA, 33458
Marizyme Inc is a multi-technology biomedical company dedicated to the accelerated development and commercialization of medical device technologies that improve patient health outcomes. Currently, the company is focused on developing three medical technology products: DuraGraft, Krillase, and MATLOC. DuraGraft is a single-use intraoperative vascular graft treatment that protects against ischemic injury and reduces the incidence and complications of graft failure, MATLOC is a point-of-care, lab-on-chip digital screening, and diagnostic device platform, initially being developed for quantitative chronic kidney disease, or CKD, assessment, and Krillase protein enzyme provides a therapeutics opportunity for wound healing, thrombosis, and pet health.
12GF Score

Get the complete analysis for MRZM

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price